Transchem Ltd
TRANSCHEMTranschem Ltd
TRANSCHEM
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 11.07 | 0.80 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.23 | 6.64 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Transchem Ltd is the largest producer of a wide range of Anathematic API`s (Anti-Parasitic) in the world.They also offer specialized range of human use APIs.The company is one of the largest suppliers of Albendazole, Clorsulon, Diminazene Diaceturate, Toldimfos Sodium, Oxfendazole, Fenbendazole, Flubendazole, Mebendazole, Nitroxynil, Ramipril from India.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Mankind Pharma Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.97 | 1.78 | 2.11 | 2.93 | 2.76 | 26.83 | 6.66 | 4.24 | 7.81 | 9.37 | ||||||||||
Raw Materials | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 2.00 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | |||||||||||
| Employee Cost | 0.28 | 0.28 | 0.24 | 0.44 | 0.62 | 0.71 | 0.75 | 0.78 | 0.75 | |||||||||||
| Selling & Administrative Expenses | 0.59 | 0.48 | 0.70 | 0.59 | 0.49 | 1.15 | 1.97 | 0.92 | 0.94 | |||||||||||
| Operating & Other expenses | 0.06 | 0.22 | 0.75 | 0.32 | 0.27 | 0.06 | 0.02 | 0.03 | 0.06 | |||||||||||
EBITDA | 1.04 | 0.79 | 0.42 | 1.58 | 1.37 | 24.89 | 3.92 | 2.51 | 5.66 | 7.37 | ||||||||||
| Depreciation/Amortization | 1.02 | 1.02 | 0.97 | 0.80 | 0.57 | 0.12 | 0.01 | 0.01 | 0.01 | — | ||||||||||
| PBIT | 0.02 | -0.23 | -0.55 | 0.78 | 0.80 | 24.77 | 3.91 | 2.50 | 5.65 | 7.37 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 0.02 | -0.23 | -0.55 | 0.78 | 0.80 | 24.77 | 3.91 | 2.50 | 5.65 | 7.37 | ||||||||||
| Taxes & Other Items | -0.03 | 0.00 | 0.64 | 0.47 | 0.38 | 0.62 | 1.04 | 1.27 | 1.45 | 1.87 | ||||||||||
| Net Income | 0.05 | -0.23 | -1.19 | 0.31 | 0.42 | 24.15 | 2.87 | 1.23 | 4.20 | 5.50 | ||||||||||
| EPS | 0.04 | -0.19 | -0.97 | 0.25 | 0.34 | 19.73 | 2.34 | 1.00 | 3.43 | 4.49 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Transchem Ltd | 14.49 | 0.80 | — |
| Sun Pharmaceutical Industries Ltd | 45.62 | 6.51 | 0.74% |
| Mankind Pharma Ltd | 62.83 | 12.55 | — |
| Cipla Ltd | 28.94 | 4.45 | 0.88% |
Price Comparison
Compare TRANSCHEM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
TRANSCHEM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Transchem rose 48.45% to Rs 1.44 crore in the quarter ended September 2024 as against Rs 0.97 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
Transchem will hold a meeting of the Board of Directors of the Company on 15 October 2024.Powered by Capital Market - Live
Transchem announced that the Annual General Meeting (AGM) of the company will be held on 24 August 2024.Powered by Capital Market - Live
Net profit of Transchem rose 95.29% to Rs 1.66 crore in the quarter ended June 2024 as against Rs 0.85 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live
BRIEF-Transchem Ltd Disposes Undertaking For 260 Mln Rupees - Investing.com India
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 21.66%, vs industry avg of 9.04%
Constant Market Share
Over the last 5 years, market share stayed at 0%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 68.41%, vs industry avg of 15.28%